2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Biglari Holdings reported second-quarter 2026 net earnings of $39.9 million, down from $50.9 million in the second quarter of 2025, as investment gains fell to $45.3 million from $61.4 million. Pre-tax operating earnings rose to $6.3 million from $3.7 million, while first-half pre-tax operating earnings fell to $2.1 million from $13.7 million, so shareholders see mixed results across the periods.
Q2 2026 pre-tax operating earnings were $6.3 million, versus $3.7 million in Q2 2025.
Q2 2026 investment gains were $45.3 million, versus $61.4 million in Q2 2025.
First six months 2026 net earnings were $25.4 million, versus $17.7 million in the same period of 2025.
Steak n Shake same-store sales rose 13.8% in Q2 2026 for company-operated and franchise-partner-operated restaurants.
Global Self Storage reported second quarter 2026 results for the period ended June 30, 2026. Total revenues rose 0.6% to $3.2 million and net income rose 24.9% to $830,000, but operating income fell 16.3% and FFO fell 10.7% to $978,000, with same-store NOI down 3.8%, mainly because of higher employment and property tax costs. The quarterly dividend of $0.0725 per share was maintained.
Total revenues rose 0.6% to $3.2 million; same-store occupancy was 94.7%, unchanged from June 30, 2025.
Net income rose to $830,000, or $0.07 per diluted share, from $664,000, or $0.06, a year earlier; the filing attributes part of the change to an unrealized gain on marketable equity securities of $266,394.
FFO fell 10.7% to $978,000 ($0.09 per diluted share) and AFFO fell 8.9% to $1.1 million; same-store cost of operations rose 8.1%.
Quarterly dividend of $0.0725 per share was declared on June 1, 2026 and maintained.
NI Holdings reported second-quarter 2026 net income of $146,000, or $0.01 per basic share, compared with a net loss of $12.1 million a year earlier. Gross premiums written fell 4.1% to $107.2 million, and net premiums earned dropped 10.9% to $65.0 million, as the company exits most of its Non-Standard Auto business. The combined ratio improved to 107.7% from 125.1%, mainly on lower catastrophe losses and favorable prior-year reserve development, so shareholders see a return to a small quarterly profit on lower premium volume.
Q2 2026 net income of $146,000 and basic EPS of $0.01, versus a net loss of $12.1 million and basic loss per share of $(0.57) in Q2 2025
Gross premiums written of $107.2 million, down 4.1%; Non-Standard Auto fell 98.9% as the company exits most of the segment
Combined ratio of 107.7% versus 125.1%; pre-tax catastrophe loss of $15.0 million for the quarter
Six-month net income of $12.7 million and basic EPS of $0.61 for the period ended June 30, 2026
HEI reported second-quarter 2026 GAAP net income of $123 million, or $0.71 per diluted share, up from $26 million, or $0.15, a year earlier. The result includes a $101 million after-tax non-cash gain from remeasuring the remaining Maui wildfire settlement liability to present value, while Core net income, which excludes wildfire and Pacific Current review items, fell to $22 million, or $0.13 per share, from $35 million, or $0.20.
Total revenues were $939.7 million, compared with $746.4 million in the second quarter of 2025.
Core net income was $22 million, or $0.13 per diluted share, versus $35 million, or $0.20, in the second quarter of 2025; Hawaiian Electric cited higher interest expense and higher O&M.
The remaining settlement liability was reduced from $1.44 billion to $1.30 billion, producing a $154 million pre-tax benefit.
On July 17, HEI submitted an IGP Request for Proposals to the PUC seeking about 1,650 gigawatt-hours of variable renewable energy, 465 megawatts of grid forming resources and 111 megawatts of firm generating capacity.
aTyr Pharma reported a second quarter 2026 net loss of $10.3 million, or $0.11 per share, down from $19.5 million, or $0.22 per share, a year earlier, and announced a workforce reduction of about 60%. The company is focusing its spending on efzofitimod, with cash of $58.9 million at June 30, 2026, which it says will fund operations into late 2028; shareholders face a smaller loss but a shrinking cash balance and leadership changes.
Q2 2026 net loss was $10.3 million, or $0.11 per share, versus $19.5 million, or $0.22 per share, in Q2 2025.
Cash, cash equivalents, restricted cash and investments were $58.9 million at June 30, 2026, down from $80.9 million at December 31, 2025.
CFO Jill Broadfoot steps down September 30, 2026; Brandon Yaras becomes CFO October 1, 2026. General Counsel Nancy Denyes also steps down September 30, 2026.
Restructuring is expected to cut annualized operating expenses by about $13 million beginning in Q4 2026; the company is awaiting FDA comments on its Phase 3 protocol by the end of August 2026.
Ultralife reported second-quarter 2026 revenue of $47.9 million, down 1.3% from $48.6 million a year earlier, while GAAP earnings per share rose to $0.15 from $0.05. Gross margin improved to 28.9% from 23.9%, helped by a $1.1 million net IEEPA tariff refund, and backlog reached $117.5 million, which the company said is the highest in its history. The mix of a sales decline alongside higher profit makes the quarter's results mixed for shareholders.
Revenue was $47.9 million versus $48.6 million in Q2 2025; Battery & Energy Products sales fell 3.7% to $44.2 million, and Communications Systems sales rose 39.3% to $3.8 million.
GAAP EPS was $0.15 versus $0.05; adjusted EBITDA was $6.1 million versus $4.1 million.
Gross margin was 28.9%; excluding the $1.1 million net IEEPA refund, it was 26.6%.
Operating income was $3.4 million, including $0.9 million in one-time costs, versus $2.3 million a year earlier.
Xenetic Biosciences reported results for the quarter ended June 30, 2026. Royalty revenue rose about 12% to about $0.7 million, but the net loss widened to about $0.9 million from about $0.7 million, mainly because general and administrative expenses rose about 64% on higher legal costs tied to its strategic review. Cash and cash equivalents fell to about $6.5 million from about $7.9 million at December 31, 2025.
Royalty revenue was about $0.7 million, up from about $0.6 million, primarily from the Takeda sublicense agreement
General and administrative expenses were about $1.1 million, up about 64%, mainly on higher legal expenses tied to the strategic review
Research and development expenses fell about 16% to about $0.6 million, mainly on lower manufacturing development efforts and reduced consulting costs
Cash and cash equivalents were about $6.5 million at June 30, 2026, versus about $7.9 million at December 31, 2025
Kestrel Group reported second quarter 2026 results on August 7, 2026, with a net loss of $8.1 million, or $1.03 per share, and total revenues of $6.7 million. Program Services fee revenue rose to $3.7 million and premium produced reached $109.6 million, both well above the second quarter of 2025, while the Legacy Reinsurance segment posted an underwriting loss of $1.3 million. For shareholders, the filing shows fast growth in the fee-based business alongside a continuing net loss.
Net loss of $8.1 million, or $1.03 per share, in the second quarter; book value per common share was $14.57 at June 30, 2026.
Program Services fee revenue was $3.7 million, up 587.9% from the second quarter of 2025; premium produced by client programs was $109.6 million, up 479.8%.
Legacy Reinsurance segment had an underwriting loss of $1.3 million in the second quarter, including $0.7 million of severance-related costs in the Diversified business.
Total assets were $919.6 million and shareholders' equity was $114.0 million at June 30, 2026.
Calumet reported a second-quarter 2026 net loss of $95.9 million, or $1.09 per basic share, compared with a net loss of $147.9 million, or $1.70 per share, a year earlier. Sales rose to $1,445.1 million from $1,026.6 million, and Adjusted EBITDA rose to $159.3 million from $55.1 million, though the filing notes non-cash RINs expense of $163.6 million weighed on results and the six-month net loss widened to $412.9 million.
Q2 2026 net loss of $95.9 million vs. $147.9 million in Q2 2025; basic EPS of $(1.09) vs. $(1.70)
Q2 2026 sales of $1,445.1 million vs. $1,026.6 million; Adjusted EBITDA of $159.3 million vs. $55.1 million
Specialty Products and Solutions Adjusted EBITDA of $161.7 million vs. $66.8 million; Montana/Renewables Adjusted EBITDA with Tax Attributes of $26.6 million vs. $16.3 million
On July 15, 2026, the company redeemed $100 million of 9.75% Senior Notes due 2028; $115 million of debt retirement in July was cited
Dauch reported second-quarter 2026 sales of $2.96 billion, up from $1.54 billion a year earlier, mainly because of the Dowlais acquisition. Net income attributable to Dauch fell to $1.0 million, or $0.00 per diluted share, from $39.3 million, or $0.32 per share, while adjusted EPS slipped to $0.32 from $0.34. The company raised the low end of its full-year 2026 sales and adjusted EBITDA ranges.
Q2 2026 sales $2.96 billion vs. $1.54 billion in Q2 2025; Adjusted EBITDA $389.6 million vs. $202.1 million
Net income attributable to Dauch $1.0 million vs. $39.3 million; diluted EPS $0.00 vs. $0.32
Adjusted EPS $0.32 vs. $0.34 a year earlier; Adjusted free cash flow $148.4 million vs. $48.7 million
Take-Two Interactive reported fiscal first-quarter 2027 results for the period ended June 30, 2026. GAAP net revenue rose to $1.53 billion from $1.50 billion, but Net Bookings fell 3% to $1.39 billion and the GAAP net loss widened to $34.1 million, or $0.18 per share, from $11.9 million, or $0.07 per share, a year earlier. The company reiterated its fiscal 2027 Net Bookings outlook of $8.0 to $8.2 billion and guided to a fiscal second-quarter net loss of $157 million to $140 million.
Net Bookings fell 3% to $1.39 billion; GAAP net revenue rose to $1.53 billion from $1.50 billion
GAAP net loss was $34.1 million, or $0.18 per share, including a $43.4 million impairment charge tied to an unannounced third-party title
Fiscal 2027 Net Bookings outlook of $8.0 to $8.2 billion reiterated; Grand Theft Auto VI launch set for November 19, 2026
Fiscal second-quarter outlook: GAAP net loss of $157 million to $140 million and Net Bookings of $1.62 billion to $1.67 billion
TDS reported second quarter 2026 total operating revenues of $309.3 million, up from $298.5 million a year earlier, and net income attributable to common shareholders of $281.1 million, compared with a loss of $5.7 million in the prior-year quarter. TDS Telecom lowered its 2026 revenue and Adjusted EBITDA guidance, while Array raised its Adjusted EBITDA guidance, and the Q2 results include $409.8 million of gains on Array license sales.
Total operating revenues $309.3 million vs. $298.5 million in Q2 2025; net income attributable to TDS common shareholders $281.1 million vs. a $(5.7) million loss
Diluted EPS from continuing operations $2.24 vs. $(0.05) a year earlier
TDS Telecom 2026 revenue guidance cut to $1,000-$1,025 million from $1,015-$1,055 million; Adjusted EBITDA cut to $310-$330 million from $310-$350 million; capital expenditure guidance raised to $625-$675 million
Array 2026 Adjusted EBITDA guidance raised to $220-$235 million from $200-$215 million
Sylvamo reported a second-quarter 2026 net loss of $11 million, compared with net income of $15 million a year earlier, while net sales rose to $806 million from $794 million. Adjusted EBITDA fell to $60 million from $82 million, and free cash flow was negative $23 million, so shareholders face weaker profit in the quarter despite higher sales. Management said it expects a much better earnings performance in the second half of 2026.
Net loss of $11 million, or $0.28 per diluted share, versus net income of $15 million, or $0.37 per share, in Q2 2025
Net sales of $806 million, up from $794 million a year earlier and $755 million in Q1 2026
Adjusted EBITDA of $60 million versus $82 million in Q2 2025; free cash flow was negative $23 million
A $12 million valuation allowance on certain foreign deferred tax assets drove the effective tax rate to 1200%
Minerva Neurosciences reported second quarter 2026 results, showing GAAP net income of $17.5 million, driven by a $27.6 million non-cash gain on its warrant liability. Adjusted net loss widened to $7.8 million from $3.0 million a year earlier, and cash, equivalents and marketable securities fell to $75.4 million from $82.4 million at December 31, 2025, so shareholders face higher operating costs ahead of the confirmatory Phase 3 trial's topline data in the second half of 2027.
Q2 2026 GAAP net income was $17.5 million, or $0.36 per basic share, versus a net loss of $3.3 million a year earlier.
Six-month GAAP net loss was $107.9 million, or $2.38 per share, including an $81.8 million non-cash warrant liability loss.
R&D expense rose to $7.2 million in Q2 from $1.3 million, mainly due to the C19 trial; G&A rose to $3.5 million from $2.1 million.
Confirmatory Phase 3 C19 trial is designed to enroll 380 patients, with Phase A topline data expected in 2H 2027.
Treace Medical reported second-quarter 2026 revenue of $45.4 million, down 4% from $47.4 million a year earlier, and a net loss of $15.9 million, or $0.24 per share, versus $17.4 million, or $0.28 per share, in the same quarter of 2025. The company raised its full-year 2026 revenue guidance to $204 million to $212 million and narrowed its expected full-year Adjusted EBITDA loss to $3.0 million to $5.0 million.
Q2 2026 revenue was $45.4 million, down 4% from $47.4 million in Q2 2025; gross margin was 78.5% versus 79.7%.
Q2 2026 net loss was $15.9 million, or $0.24 per share, compared with $17.4 million, or $0.28 per share, a year earlier.
Full-year 2026 revenue guidance rose to $204 million to $212 million from $202 million to $212 million.
Full-year 2026 Adjusted EBITDA loss guidance was updated to $3.0 million to $5.0 million from $4.0 million to $6.0 million; cash usage reduction of about 50% was reiterated.
Embecta reported fiscal third-quarter 2026 revenue of $271.7 million, down 8.1% from $295.5 million a year earlier, and net income of $21.1 million, or $0.36 per diluted share, versus $0.78 a year earlier. The company reaffirmed its fiscal 2026 revenue guidance of $1,015 million to $1,035 million and raised its adjusted earnings per share guidance to $1.80 to $1.90 from $1.55 to $1.75.
Q3 revenue $271.7 million, down 8.1%; U.S. revenue down 24.6%, International up 11.5% (reported basis)
Q3 GAAP operating income $48.7 million vs. $94.0 million a year earlier; adjusted operating income $69.4 million vs. $109.1 million
Fiscal 2026 adjusted EPS guidance raised to $1.80-$1.90 from $1.55-$1.75; adjusted operating margin guidance raised to 23.50%-24.00%
Quarterly dividend of $0.01 per share declared, payable September 15, 2026 to holders of record on August 27, 2026
Canopy Growth reported fiscal first-quarter 2027 results for the three months ended June 30, 2026, with consolidated net revenue up 13% to $81.2 million (in Canadian dollars) and net loss 68% lower than a year earlier. Adjusted EBITDA loss narrowed to $3.2 million, and management said it expects further improvement in the second half of fiscal 2027 as the MTL Cannabis integration is completed, though free cash outflow rose sharply.
Consolidated net revenue of $81.2 million, up 13% from the prior-year quarter; Canada medical cannabis revenue up 22%, Storz & Bickel up 6%
Adjusted gross margin rose to 31% from 25%; consolidated gross margin was 27% versus 25%
Adjusted EBITDA loss of $3.2 million, an improvement of $4.7 million or 59% year over year
Free cash outflow increased to $25.7 million from $11.6 million, mainly due to timing of working capital items
Mobility Global reported second quarter 2026 results, its first as an independent public company after its July 1, 2026 spin-off. Revenue rose 7% while net income and diluted EPS fell 18%, and the company gave full-year 2026 revenue and adjusted EBITDA guidance and declared its first quarterly dividend of $0.06 per share.
Q2 total revenue was $468 million, up 7% from $439 million; CARFAX revenue rose 8% to $312 million and B2B rose 4% to $156 million
Q2 net income was $53 million, down 18% from $65 million; diluted EPS was $0.18 versus $0.22
Q2 adjusted EBITDA was $202 million, up 7%, with a 43% margin
Full-year 2026 guidance: revenue of $1,870 million to $1,885 million and adjusted EBITDA of $745 million to $760 million; dividend payable September 10, 2026 to holders of record on August 27, 2026
Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier, and a gross margin of 15.0%, compared with 3.8% in the prior-year quarter. The net loss widened to $12.9 million from $11.9 million, while loss per share was unchanged at $0.27, and the company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million.
Q2 2026 total revenue $8.1 million, up 10.9% from $7.3 million in Q2 2025
Net loss $12.9 million versus $11.9 million a year earlier; net loss per share $0.27 in both periods
Gross margin 15.0% versus 3.8% in Q2 2025; total operating expenses rose 8.9% to $13.5 million
Full-year 2026 revenue guidance of $37.0 million to $41.0 million reaffirmed; validation guidance raised to at least 27 from 25
Fluor reported second-quarter 2026 revenue of $4.3 billion, up 9% from a year earlier, and adjusted EPS of $0.91 versus $0.43. The company narrowed its 2026 adjusted EBITDA guidance to $500 million to $525 million from $525 million to $560 million, citing the removal of expected second-half contribution from its Mexico joint venture, and GAAP net earnings fell sharply from the prior year, which included a large equity method gain tied to the NuScale monetization.
Q2 2026 revenue was $4.3 billion versus $4.0 billion a year earlier; GAAP EPS was $0.81 versus $14.81, and adjusted EPS was $0.91 versus $0.43.
2026 adjusted EBITDA guidance was narrowed to $500 million to $525 million, down from $525 million to $560 million.
New awards were $6.1 billion versus $1.8 billion a year earlier, while ending backlog was $26.9 billion versus $28.2 billion.
Operating cash flow for the quarter was ($317) million, including a $357 million tax payment related to the NuScale monetization; the company repurchased $300 million of stock in the quarter and still targets $1.4 billion in repurchases for
Vistra reported second quarter 2026 results on August 7, 2026. Ongoing Operations Adjusted EBITDA rose to $1,767 million from $1,349 million a year earlier, while GAAP net income fell to $305 million from $327 million and operating revenues fell to $4,017 million from $4,250 million. The company reaffirmed its 2026 Ongoing Operations Adjusted EBITDA guidance of $6.8 billion to $7.6 billion.
Q2 2026 operating revenues were $4,017 million, down from $4,250 million in Q2 2025.
Net income was $305 million, including an unrealized hedge loss of $472 million on positions expected to settle in future years.
2026 Ongoing Operations Adjusted EBITDA guidance of $6.8 billion to $7.6 billion was reaffirmed.
Vistra announced Helix Digital Infrastructure with KKR, KIA, and NVIDIA, with an initial Vistra commitment of up to $1.0 billion.
ARKO reported second-quarter 2026 net income of $9.4 million, down from $20.1 million a year earlier, and Adjusted EBITDA of $72.0 million, down from $76.9 million, while revenue rose to $2.35 billion from $2.00 billion. Its subsidiary ARKO Petroleum Corp. (APC) also agreed to acquire U.S. Petroleum Partners' business for $205 million in cash plus inventory, which the company expects to add about $30 million of annualized Adjusted EBITDA. ARKO reaffirmed its full-year 2026 Adjusted EBITDA outlook of $245 million to $265 million and raised its retail fuel margin range.
Q2 2026 net income was $9.4 million versus $20.1 million in Q2 2025; the prior-year period included a $20.8 million non-cash sale-leaseback gain.
Q2 Adjusted EBITDA was $72.0 million versus $76.9 million; first-half Adjusted EBITDA rose 14.0% to $122.9 million.
APC agreed to acquire U.S. Petroleum Partners' business for $205 million in cash plus inventory cost, plus $30 million of APC Class A stock held in escrow tied to EBITDA targets.
ARKO reaffirmed 2026 Adjusted EBITDA of $245 million to $265 million and raised its average annual retail fuel margin outlook to 45.5 to 47.5 cents per gallon.
ANI Pharmaceuticals reported second-quarter 2026 total net revenues of $266.0 million, up 25.9% from a year earlier, and GAAP net income available to common shareholders of $24.7 million, or $1.05 per diluted share, versus $0.36 in the prior-year quarter. The company reaffirmed its full-year total net revenue guidance of $1,080 million to $1,140 million and adjusted non-GAAP EBITDA guidance of $285 million to $300 million, but lowered its Cortrophin Gel net revenue guidance to $520 million to $540 million from $540 million to $575 million, which matters because Cortrophin Gel is the company's largest product.
Total net revenues were $266.0 million in Q2 2026, up from $211.4 million in Q2 2025.
Diluted GAAP EPS was $1.05 versus $0.36; adjusted non-GAAP diluted EPS was $2.21 versus $1.80.
Cortrophin Gel 2026 net revenue guidance was revised to $520 million to $540 million from $540 million to $575 million; total net revenue guidance of $1,080 million to $1,140 million was reaffirmed.
The board authorized a share repurchase program of up to $100.0 million in common stock through May 2029, effective May 8, 2026.
Essent Group reported second-quarter 2026 net income of $189.7 million, or $2.08 per diluted share, compared with $195.3 million, or $1.93 per diluted share, a year earlier. Total revenues rose to $362.7 million from $319.1 million, so revenue and net income moved in opposite directions. The board also declared a $0.35 quarterly dividend, payable September 10, 2026.
Net income was $189.7 million for the quarter ended June 30, 2026, versus $195.3 million a year earlier
Diluted EPS was $2.08, versus $1.93; diluted weighted average shares were 91.4 million, versus 101.1 million
Total revenues were $362.7 million, versus $319.1 million in the second quarter of 2025
Quarterly dividend of $0.35 per share; record date August 31, 2026; payable September 10, 2026; 5.8 million shares repurchased for $348 million through July 31, 2026
Nathan's Famous reported first-quarter fiscal 2027 revenue of $54.1 million, up from $47.0 million a year earlier, but net income fell to $8.8 million from $8.9 million and diluted EPS fell to $2.14 from $2.16. The company is being acquired by Smithfield Foods for $102.00 per share in cash, and the company expects the deal to close in the second half of 2026.
Revenue was $54,062,000 versus $46,998,000 in the prior-year quarter.
Net income was $8,829,000 versus $8,928,000; diluted EPS was $2.14 versus $2.16.
Branded Product Program income from operations fell to $1,330,000 from $2,276,000, due primarily to a 22% increase in the cost of beef and beef trimmings.
Smithfield Foods merger agreement, signed January 20, 2026, provides for $102.00 per share in cash.
Spectrum Brands reported fiscal third-quarter 2026 net sales of $753.3 million, up 7.7%, but swung to a net loss from continuing operations of $20.3 million, compared with net income of $20.5 million a year earlier. The results include a one-time $60.6 million benefit from IEEPA tariff refunds and a one-time non-cash impairment charge on its Home and Personal Care business. The company raised its fiscal 2026 adjusted EBITDA expectation, excluding tariff refunds, to mid single digit growth, while net sales guidance was unchanged.
Net sales rose 7.7% to $753.3 million; Home & Garden sales rose 19.0% to $225.2 million
Net loss from continuing operations was $20.3 million, or $1.11 per diluted share, versus net income of $20.5 million, or $0.83 per diluted share, a year earlier
Adjusted EBITDA was $158.3 million, up 106.7%; excluding $60.6 million of tariff refunds, it was $97.7 million, up 27.5%
Fiscal 2026 adjusted EBITDA expectation, excluding tariff refunds, raised to mid single digit growth; net sales still expected flat to up low single digits
AdvanSix reported second-quarter 2026 sales of $421 million, up 3% from a year earlier, while net income fell to $3.2 million from $31.4 million and diluted EPS fell to $0.12 from $1.15. Adjusted EBITDA dropped 43% to $31.9 million, and the company cited lower sales volume in Plant Nutrients. The board also declared a $0.16 per share quarterly dividend, payable September 1, 2026.
Sales of $421.3 million rose 3% year over year, driven by 18% favorable pricing, partly offset by a 15% decline in volume.
Net income was $3.2 million versus $31.4 million; adjusted diluted EPS was $0.19 versus $1.24.
Adjusted EBITDA was $31.9 million, down 43%, and free cash flow was negative $10.7 million.
Quarterly dividend of $0.16 per share is payable September 1, 2026 to holders of record on August 18, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.